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Non-destructive characterisation of mesenchymal
stem cell diﬀerentiation using LC-MS-based
metabolite footprinting†
Amal Surrati,a Rob Linforth,b Ian D. Fisk,b Virginie Sottile*a and Dong-Hyun Kim*c
Bone regeneration is a complex biological process where major cellular changes take place to support
the osteogenic diﬀerentiation of mesenchymal bone progenitors. To characterise these biological
changes and better understand the pathways regulating the formation of mature bone cells, the metabolic
proﬁle of mesenchymal stem cell (MSC) diﬀerentiation in vitro has been assessed non-invasively during
osteogenic (OS) treatment using a footprinting technique. Liquid chromatography (LC)-mass spec-
trometry (MS)-based metabolite proﬁling of the culture medium was carried out in parallel to mineral
deposition and alkaline phosphatase activity which are two hallmarks of osteogenesis in vitro. Metabolic
proﬁles of spent culture media with a combination of univariate and multivariate analyses investigated
concentration changes of extracellular metabolites and nutrients linked to the presence of MSCs in
culture media. This non-invasive LC-MS-based analytical approach revealed signiﬁcant metabolic
changes between the media from control and OS-treated cells showing distinct eﬀects of MSC diﬀeren-
tiation on the environmental footprint of the cells in diﬀerent conditions (control vs. OS treatment). A
subset of compounds was directly linked to the osteogenic time-course of diﬀerentiation, and represent
interesting metabolite candidates as non-invasive biomarkers for characterising the diﬀerentiation of
MSCs in a culture medium.
Introduction
During skeletal development or fracture repair, bone is formed
by a complex process involving the osteogenic diﬀerentiation
of mesenchymal progenitors.1 This process requires a variety
of intracellular and extracellular molecular mechanisms
orchestrating specialised cell types.1,2 Mesenchymal stem cells
(MSCs) are multipotent somatic progenitors able to diﬀeren-
tiate into osteogenic, chondrogenic and adipogenic lineages.3
Their capacities to generate new osteoblasts, the bone-forming
cell type, and the possibility of harvesting them from bone
marrow collections have made them a promising candidate for
therapeutic approaches to skeletal repair.4 Numerous in vitro
studies have demonstrated the eﬀect of osteoinductive treat-
ment combining dexamethasone, ascorbic acid, and beta-
glycerophosphate (βGP) on MSC osteogenesis. Dexamethasone
induces osteogenesis in vitro through activating WNT/
β-catenin signalling-dependent Runx2 expression,5 whereas
ascorbic acid increases collagen type 1 secretion.6,7 βGP pro-
vides inorganic phosphate (Pi) that facilitates intracellular sig-
nalling molecules.8–10
Since metabolites provide the phenotypic outcome of gene
expression or metabolic activities of a cell, global metabolite
profiling can give a rapid snapshot of the cell physiology by
monitoring concentration changes of a broad range of meta-
bolites and provide insight into relationships between geno-
type and phenotype.11,12 Therefore, metabolomics has been
used widely for understanding underlying molecular processes
in applications for human health and disease including bio-
marker and drug discovery.13 Recent studies have reported
changes in specific metabolites extracted from mesenchymal
cultures in response to diﬀerent microenvironment pro-
perties.14 Furthermore, parathyroid hormone (PTH) eﬀect on
mouse osteogenic lineage was shown to be negatively influ-
enced by suppressing cellular oxidation of glucose through tri-
carboxylic acid cycle (TCA cycle).15 Also, the stimulation of
glutamine biosynthesis through WNT signalling boosts the
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formation of osteoblasts.16 In addition, studying mesenchymal
stem cells in terms of osteogenic metabolomics would not
only extend the understanding of bone tissue biology but also
provide new approaches for pharmacological and clinical
developments.
Metabolite profiling of intracellular metabolites is informa-
tive to understanding complex biological processes and
systems, but this approach requires complicated sample prepa-
ration, including the rapid quenching of metabolism and
extraction of intracellular metabolites from cells. Incomplete
quenching and extraction methods could lead to biased
quantification, due to rapid turnover and loss of metabolites.
Therefore, an alternative approach can be the measurement of
extracellular metabolites that are secreted and/or excreted
from cells into their growth media or nutrients which are con-
sumed by cells. This metabolite footprinting technique
requires minimum sample preparation and can provide sig-
nificant information to understand the microenvironment of a
cell of interest,17,18 as used for human hepatic stem cells
(hHpSCs).19
Liquid chromatography (LC)-mass spectrometry (MS) is a
powerful tool for the quantification of small molecules, as well
as the identification of known and unknown metabolites in
biological samples. Recently, LC-MS-based approaches have
been employed widely for the quantitative analysis of extra-
cellular metabolites and nutrients in a growth medium,20 it is
therefore reasonable to speculate that MSC diﬀerentiation
could be characterised by its distinct metabolic footprint,
including metabolite secretion and/or excretion and nutrient
consumption, which may be unique to the specific metabolic
pathways activated during MSC diﬀerentiation. The pathways
identified by LC-MS-based footprinting can be used to
monitor stem cell diﬀerentiation through the analysis of
metabolite changes not only between various cell fates, but
also at diﬀerent stages within specific lineage maturation.
Established cell phenotyping methods including gene
expression analysis, protein immunodetection and flow cyto-
metry are widely used to produce high resolution molecular
phenotyping at the cellular and population level,21–23 however
these approaches involve invasive and cell destructive steps
which limit their application to live cell monitoring. This
study proposes a non-invasive analysis for metabolic changes
occurring in the culture medium during MSC osteogenic
diﬀerentiation, and for the first time, demonstrates a quanti-
tative time-point analysis of key molecular changes occurring
during MSC osteogenesis.
Material and methods
Materials were purchased from Life Technologies (Paisley, UK)
unless otherwise stated.
Cell culture and diﬀerentiation assay
Mouse mesenchymal stem cells (MSCs)24 were seeded in
22.5 mm × 75.5 mm vials (Fisher Scientific, UK) as six repli-
cates at density of 3 × 104 cells per mL in a standard MSC
medium consisting of Dulbecco’s Modified Eagle’s Medium
(DMEM), 10% fetal calf serum (FCS), 1 mM L-glutamine, 1%
non-essential amino acids and 10% antibiotics, and incubated
at 37 °C in 5% CO2. Confluent cells treated with an osteogenic
medium consisting of the standard MSC medium, 100 nm dex-
amethazone (Sigma-Aldrich, Gillingham, UK), 0.05 mM
L-ascorbic acid 2-phosphate (Acros Organics, Geel, Belgium)
and 10 mM beta glycerophosphate (βGP, Sigma-Aldrich), and
treated for 15 days with medium changes every 2 days. Cell
maintained in the standard MSC medium were used as a
control medium sample. All supplements were prepared
according to the manufacturer’s guidelines. The same media,
reagents and supplements were used throughout the experi-
ment for consistency.
Calcium deposits were analysed using Alizarin Red staining.
At the stated time point, cells from 4 replicates were trypsi-
nised and pellets were smeared onto glass slides, air dried,
fixed with 100% methanol and washed with distilled water.
Slides were incubated in 1% Alizarin Red staining solution
(Sigma-Aldrich) for 10 min at room temperature, and washed
with distilled water until all excess stain was removed. Mineral
deposits were then observed using a Nikon Eclipse Ni90 light
microscope. In parallel, alkaline phosphatase (ALP) activity
was measured in the remaining two culture replicates using
100 µL SIGMA FAST p-Nitrophenyl Phosphate reagent (Sigma-
Aldrich) for 20 min at 37 °C, 5% CO2. 100 µL from each
sample transferred to a 96 well plate were analysed in triplicate
using an Tecan Infinite 200 plate reader and Tecan-i-control
1.10 software to measure absorbance at 405 nm. Quantifi-
cation of ALP absorbance was not normalized to the cell
number present in each vial.
Metabolites extraction
At day 5, 10 and 15, 1 mL of the medium in each culture (MSC-
conditioned medium) was collected and centrifuged at 7378 g
for 5 min. 250 µL of the collected medium were transferred to
a new tube for extraction and protein precipitation by adding
750 µL of cold methanol in a ratio of 1 : 4, then mixing vigor-
ously and incubating at −20 °C for 20 min. After incubation,
samples were centrifuged at 13 200 g at 4 °C for 10 min, trans-
ferred to pre-cooled tubes and stored at −80 °C until LC-MS
analysis. Samples of fresh standard MSC medium and OS
medium were processed in parallel as no cells controls. All
samples were prepared as six biological replicates, and the
experiment was run as two successive independent repeats. An
equal mix of all samples was prepared as quality control (QC)
for instrument performance assessment.25
Analytical methodologies
For metabolite footprinting of spent culture media, LC-MS was
performed on an Accela system coupled to an Exactive MS
(Thermo Fisher Scientific, Hemel Hempstead, UK). Spectral
data was acquired in full scan ion mode (m/z 70–1400, resolu-
tion 50 000) in both positive and negative electrospray ionis-
ation modes. The probe temperature and capillary temperature
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were maintained at 150 and 275 °C, respectively. The cali-
bration mass range was extended to cover small metabolites by
inclusion of low-mass contaminants with the standard
Thermo calibration mixture masses (below m/z 1400),
C2H6NO2 for positive ion electrospray ionisation (PIESI) mode
(m/z 76.0393) and C3H5O3 for negative ion electrospray ionis-
ation (NIESI) mode (m/z 89.0244). Chromatographic separation
was carried out using a ZIC-pHILIC (150 mm × 4.6 mm, 5 µm
column, Merck Sequant) maintained at 45 °C and a flow rate
of 300 µL min−1 as previously described in ref. 26. Briefly, the
mobile phase consisted of (A) 20 mM ammonium carbonate in
water, (B) 100% acetonitrile which were eluted with a linear
gradient from 80% B to 5% B over 15 min, followed by a 2 min
linear gradient from 5% B to 80% B, and 7 min re-equili-
bration with 80% B. The injection volume was 10 µL and
samples were maintained at 4 °C.
Metabolites identification process
LC-MS raw data from medium samples (control medium
samples and their blanks, OS treated medium samples and
their blanks and QC samples and reagent blanks) were pro-
cessed with XCMS for untargeted peak-picking,27 and peak
matching and annotation of related peaks were carried out
using mzMatch.28 IDEOM with the default parameters was
used for noise filtering and putative metabolite identification.
Level 1 metabolite identification was performed by matching
accurate masses and retention times of authentic standards
which were run on the same instrument according to the
metabolomics standards initiative,29,30 but Level 2 putative
identification was considered when standards were not avail-
able and predicted retention times were employed.
Supervised orthogonal partial least squares discriminant
analysis (OPLS-DA)31 was initially performed by SIMCA-P
13.0.2 version (Umetrics AB, Umea, Sweden) (i) for general
visualisation of metabolite diﬀerences between control
medium samples and their controls, and OS treated medium
samples and their blanks, (ii) to identify the temporal shift
within control and OS treated conditions, and (iii) to observe
the diﬀerences between control and OS treated medium
samples (n = 6 in each group). Mass ions for discriminant bio-
markers were selected by variable importance in projection
values (VIP) where VIP values greater than one were considered
as potential biomarkers. In addition to the investigation of VIP
scores from OPLS-DA for the discovery of key discriminatory
metabolites, univariate analysis was applied as a final feature
selection. One-way ANOVA was carried out using Metaboanalyst
that is a web server for metabolomic data analysis and
interpretation,32 and was used to evaluate levels of significant
diﬀerence between control and OS treated media.
Results and discussion
In vitro model of osteogenic diﬀerentiation
In order to model the cellular changes occurring upon osteo-
genic induction, mesenchymal stem cells (MSC) were treated
in vitro to induce osteogenic diﬀerentiation (Fig. 1), and the
cultures were analysed at day 5, 10 and 15 to investigate
changes in alkaline phosphatase activity (ALP) and mineral
content, which are two major characteristics of bone for-
mation.33 No mineralisation was detected with standard
medium, whilst OS conditions showed mineral deposits that
were positively stained at day 10 and more strongly at day 15
(Fig. 1A). ALP levels increased at early stages of OS induction
with significant elevation toward day 10, followed by a notable
decline toward day 15, when ALP activity returned to compar-
able levels to standard control medium (Fig. 1B), in line with
previous reports.34 The ALP changes and associated mineral
deposits accumulation during osteogenic treatment containing
ascorbic acid and beta glycerophosphate confirmed MSC
diﬀerentiation during the 15-day time course.35,36
Multivariate analysis of LC-MS profiling data
In order to investigate the metabolic changes occurring in the
MSC culture medium over the 15-day treatment period (ESI
Fig. 1†), samples from standard medium cultures, OS-treated
cultures, and their respective blank media (not exposed to
cells) were analysed by LC-MS (ESI Fig. 2 and 3†). LC-MS data
from these MSC-conditioned or blank media samples were
transformed into 2D matrix by mzMatch, to introduce an exact
mass and retention time for each mass ion. OPLS-DA was then
performed to determine the overall biological variation
between all conditions, and to identify noticeable trends upon
conditioning with MSCs, and over the course of the OS
treatment.
OPLS-DA scores plots showed reproducible clustering of six
biological replicates for each sample group, and highlighted
clear diﬀerences between the diﬀerent conditions tested
(Fig. 2). The OPLS-DA models were cross-validated by calculat-
ing Q2 which is an estimate of the predictive ability of the
model. The non-conditioned fresh media (blanks) analysed in
the absence of MSCs showed distinct clusters from each spent
culture medium conditioned in the presence of MSCs (control
and OS medium samples) with R2 and Q2 values of 0.841 and
0.644, respectively (Fig. 2A). Similarly, samples exposed to
osteogenic medium clustered in a diﬀerent quadrant from the
standard control medium samples in the OPLS-DA scores plot.
This multivariate analysis clearly showed that LC-MS-based
metabolite footprinting was able to non-invasively detect
changes of metabolites according to cell diﬀerentiation. From
separate scores plots of either standard control or OS medium
conditioned (Fig. 2B and C), the scores of all cell-conditioned
samples (at day 5, 10 and 15) showed a significant shift away
from their respective fresh media (blanks), indicating a distinc-
tive MSC-related metabolomic signature. The obtained R2 and
Q2 values from OPLS-DA models of each sample were 0.991
and 0.756 for standard control medium, and 0.992 and 0.777
for OS medium conditioned, respectively, demonstrating an
acceptable model. As clearly shown in Fig. 2B and C, the
scores of fresh media in the absence of cells are observed in
the middle left hand side, and as the length of culture under
treatment increased, the cluster spread from left to right
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(D5 and 10) and then goes to the bottom (D15). These resul-
tant scores plots clearly showed cluster patterns directly
related to the length of cell culture treatment. It is therefore
reasonable to consider that the metabolite footprinting data
from MSC cell culture media analysed using LC-MS contains
valuable information regarding metabolite secretion/excretion
and nutrient consumption relevant to the metabolic eﬀect of
MSC diﬀerentiation.
Changes in MSC medium were monitored over the 15-day
diﬀerentiation time-course. When comparing the three time-
points analysed within each treatment group, distinct diﬀer-
ences were observed suggesting dynamic changes in the MSC
culture medium over time following the same trend in both
standard and OS treatment conditions, with datasets at early
culture stages (day 5 and 10) showing closer metabolomic
proximity than the late time-point (day 15).
Feature selection: analysis of MSC culture samples versus
blank media without cells
To determine which mass ions contributed to the clusters and
trends between MSC cultured media and medium only blank
samples, group comparisons were performed between fresh
medium (day 0) and day 15 samples within the OPLS-DA
models. Key mass ions for discriminant biomarkers were
Fig. 1 Osteogenic diﬀerentiation in MSC cultures after 5, 10 and 15 days. (A) Alizarin Red staining of cells treated with either control (top panel) or
OS medium (bottom panel) showing no mineralization in control medium, while under OS treatment calcium deposits were identiﬁed at D10 and 15.
(B) ALP activity assay showing an increase in response to OS treatment at day 5 and 10 (***p < 0.001, **p < 0.01, *p < 0.05; n = 3). Scale bar =
200 µm.
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selected by VIP values higher than one were considered as
potential key mass ions. In addition to the multivariate analy-
sis, univariate one-way ANOVA testing was also performed to
identify significant compounds consumed and excreted by
MSCs (both in standard and OS treatments) compared to their
medium-only blanks over time. Key mass ions were also
selected from the univariate analysis with the false discovery
rate Q ≤ 0.05. The analysis was repeated in two independent
Fig. 2 OPLS-DA scores plots of MSC medium samples from standard and OS-treatment, and their corresponding medium-only blanks, analysed
after 5, 10 and 15 days in culture. (A) Combined standard and OS treated MSC-conditioned samples and their respective medium-only blanks (R2 =
0.841 and Q2 = 0.644) (B) Untreated control medium MSC samples and their corresponding medium-only blanks (R2 = 0.991 and Q2 = 0.756). (C)
OS medium-treated MSC samples and their corresponding medium-only blanks (R2 = 0.992 and Q2 = 0.777). Each condition was analysed in 6 bio-
logical replicates. Arrows indicate the metabolic proﬁle changes between the sample conditions.
Analyst Paper
This journal is © The Royal Society of Chemistry 2016 Analyst
Pu
bl
ish
ed
 o
n 
18
 A
pr
il 
20
16
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ot
tin
gh
am
 o
n 
27
/0
4/
20
16
 2
2:
00
:3
0.
 
View Article Online
experiments, and the combination of multi- and univariate
analyses identified 215 metabolites showing variation between
the MSC-conditioned medium samples compared to matching
medium-only blanks, both under control medium and OS
treatment (ESI Table 1†). A pie chart showing the classification
of 195 metabolites according to their metabolism was gener-
ated by focusing on compounds selectively increased in the
presence of MSCs (Fig. 3), and a heatmap showing their fold
changes is presented in ESI Fig. 4.†
This first analysis identified significant metabolomic
changes related to MSC conditioning of the culture medium,
such as the increase of deoxyuridine, orotidine, indole-3-acet-
aldehyde, acronycidine, (S)-3-methyl-2-oxopentanoic acid,
1-methylnicotinamide, 2-hydroxy-4-methylthiobunoate, 3-(4-
hydroxyphenyl)pyruvate (Fig. 4). Some of these compounds are
linked to cell proliferation. For instance, deoxyuridine is
involved in the synthesis of nucleosides, the structural sub-
units of nucleic acids,37 and are known to fluctuate during
DNA synthesis or the S-phase of the cell cycle.38,39 Similarly,
orotidine is involved in nucleotide synthesis through pyrimi-
dine synthesis (KEGG pathway; MAP00240). In our study,
LC-MS-based footprinting detected changes in deoxyuridine
Fig. 3 Functional categorisation of the nutrients and metabolites produced by MSCs in their culture medium. (A) 195 metabolites identiﬁed by
LC-MS are categorised based on their biological function. (B) Venn diagram showing that within the total 195 identiﬁed metabolites, 10 were selec-
tively increased in untreated control and 21 metabolites in OS treated medium.
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Fig. 4 MSC-related metabolites found to increase over time in culture medium in the presence of MSCs, both in control medium (blue triangle)
and OS medium (red square), at day 5, 10 and 15 of culture. Zero peak intensity was deﬁned by the level detected in medium only blanks
(****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05; n = 6).
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and orotidine in culture medium conditioned by MSCs.
During OS treatment, deoxyuridine significantly increased
while orotidine decreased compared to MSC conditioned
medium under control conditions. This finding could suggest
epimetabolomic changes during nucleotide synthesis over the
osteogenic diﬀerentiation time-course.
In addition, L-tryptophan, which is an essential amino acid
for protein synthesis40 and one of the essential component of
DMEM, was found at comparable levels in all medium con-
ditions including medium only blanks (data not shown).
Indole-3-acetaldehyde, a derivative of L-tryptophan reported
during gluconeogenesis,41,42 was significantly increased in
medium conditioned by MSCs, suggesting that indol-3-acet-
aldehyde might have been formed from the L-tryptophan
present in the culture medium (DMEM). Our data also showed
a significant elevation in 1-methylnicotinamide upon MSC
culture and during osteogenesis compared to the control
medium conditions. 1-Methylnicotinamide is reported as a
nicotinamide metabolite,43 and a reduction in nicotinamide
adenine dinucleotide (NADH) intensity has previously been
observed in MSCs following osteogenic diﬀerentiation,44
suggesting that metabolomic changes in NADH metabolism
may reflect diﬀerent stages of osteogenic maturation.
Non-invasive metabolic profiling of MSC osteogenic
diﬀerentiation
Further investigation was carried out to identify metabolomic
diﬀerences between MSC-conditioned medium produced
under standard and OS treatment. Out of 195 compounds
initially detected as potential biomarkers, 21 metabolites
increased specifically during OS diﬀerentiation of MSCs
(Table 1).
Measurements of these compounds over the culture time-
course showed significant upregulation of citrate, cis-aconitate,
2-oxoglutarate (α-ketoglutarate derivative), succinate, glycerol
and orthophosphate in MSC medium upon OS exposure
(Fig. 5). Conversely, the concentration of sn-glycerol-3-phos-
phate was rapidly diminished from the OS-treated medium
over time. Interestingly, compounds such as sn-glycerol 3-phos-
phate, glycerol, orthophosphate, glutamate and citrate are
linked to the degradation of βGP added to OS medium, which
is hydrolysed by the glycerol 3-phosphatase enzyme to glycerol
and orthophosphate during glycerolipid metabolism (KEGG
REACTION: R00841) (KEGG ENZYME: EC3.1.3.19). Higher
levels of glycerol and orthophosphate were consistently
detected throughout osteogenic diﬀerentiation time-course
(Fig. 5F and G). Although orthophosphate was increased with
osteogenic treatment, the LC-MS technique detected low con-
centration of this compound in the standard medium control,
possibly due to other metabolic processes such as glutamine
metabolism by L-glutamine synthetase enzyme (ATP + L-glut-
amate + ammonia ⇔ ADP + orthophosphate + L-glutamine)
(KEGG REACTION: R00253) and the citrate cycle (ATP + citrate
+ CoA ⇔ ADP + orthophosphate + acetyl-CoA + oxaloacetate)
(KEGG ENZYME: 2.3.3.8). Furthermore, orthophosphate could
play a role in ALP inhibition at the late stages of osteogenic
diﬀerentiation by binding to the enzyme active site and inhi-
biting its activity.45 This could indicate a link between the
noticeable orthophosphate elevation toward day 15 of diﬀeren-
tiation and the reduction in ALP level in day 15 OS-treated
cells (Fig. 1B).
Table 1 The most signiﬁcant metabolites that were increased speciﬁcally during OS diﬀerentiation analysed by OPLS-DA and one-way ANOVA
Exact mass RT (min) Formula Putative metabolite ID confidence Identifier (PubChem) ↑ OS
214.0244 9.68 C5H11O7P 2-Deoxy-D-ribose 5-phosphate L2 45934311 +
112.0161 11.85 C5H4O3 2-Furoate L2 6919 ++
120.0059 11.54 C3H4O5 2-Hydroxymalonate L2 45 +
192.0805 8.73 C19H28O6S 3b-16a-Dihydroxyandrostenonesulfate L2 22833522 +
174.0164 11.70 C6H6O6 cis-Aconitate L2 643757 ++
192.0270 11.88 C6H8O7 Citrate L2 311 ++
276.0958 10.99 C10H16N2O7 GammaGlutamylglutamicacid L2 92865 ++
92.0474 8.77 C3H8O3 Glycerol L1 753 +
246.0505 8.84 C6H15O8P Glycerophosphoglycerol L2 439964 +
262.0148 11.26 C9H10O7S Homovanillicacidsulfate L2 29981063 +
166.0477 9.49 C5H10O6 L-Arabinonate L2 5459849 +
120.0423 7.90 C4H8O4 L-Erythrulose L2 5460032 +
72.0210 8.76 C3H4O2 Methylglyoxal L1 880 +
146.0215 11.92 C5H6O5 Methyloxaloacetate L2 440890 +
237.0849 11.88 C8H15NO7 N-Acetyl-D-glucosaminate L2 16126799 ++
217.1314 8.08 C10H19NO4 O-Propanoylcarnitine L2 107738 ++
97.9771 10.61 H3O4P Orthophosphate L2 1061 +
102.0681 5.26 C5H10O2 Pentanoate L2 114781 ++
173.9986 4.89 C6H6O4S Unknown +
118.0267 10.09 C4H6O4 Succinate L1 1110 ++
139.9780 12.05 C2H4O5S Sulfoacetate L2 31257 +
+ indicates the increase during OS treatment only compared to control medium samples, and ++ indicates an increase over time toward terminal
diﬀerentiation (day 15). ID confidence: metabolite identification level according to the metabolomics standards initiative;29,30 L1 – Level 1,
L2 – Level 2.
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Fig. 5 Metabolite changes identiﬁed in the culture medium MSC-related metabolites found to increase over time in culture medium in the pres-
ence of MSCs under OS treatment (red square) compared to control medium (blue triangle), at day 5, 10 and 15 of treatment (****p < 0.0001,
***p < 0.001, **p < 0.01, *p < 0.05; n = 6).
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A subset of compounds diﬀerentially detected in the OS
culture medium could also be related to the Krebs cycle
(Fig. 6). Citrate, cis-aconitate, α-ketoglutarate, succinate, malo-
nate and malate are component of the Krebs cycle or Tricar-
boxylic cycle (TCA cycle), which represents an essential energy
metabolism pathway in cells as first described by
H. A. Krebs.46 In the typical Krebs cycle, pyruvate produced by
glycolysis is converted to acetyl-CoA by the pyruvate dehydro-
genase complex. Acetyl-CoA then enters the mitochondria and
combines to oxaloacetate to produce citrate (through the
citrase synthesase enzyme) which is then utilised to form cis-
aconitate. The later becomes isocitrate, is then oxidised to
form oxoglutarate (α-ketoglutarate derivative), followed by con-
version of succinyl-CoA to succinate with GTP production. Suc-
cinate will then converts to fumarate and malate, completing
the cycle to form oxaloacetate. Significant changes in levels of
Krebs cycle metabolites were identified in the medium of MSC
cultures under both standard and osteogenic conditions.
LC-MS analysis indicated a substantial and gradual increase in
citrate and cis-aconitate production throughout osteogenic
induction (peaking at day 15) in comparison with standard
medium control. Interestingly, citric acid has been described
as essential for bone organic nanostructure47 and bone tissue
engineering in bone marrow-derived rat MSCs.48 This suggests
that the change in citrate levels may be linked to osteogenic
treatment. cis-Aconitate is an intermediate in cell respiration,
however there is no report to date describing the possible
eﬀect of this compound on osteogenesis.
Fig. 6 Biological pathways highlighted by the compounds diﬀerentially detected in MSC-conditioned culture medium (asterisk). (A) Components
involved in cell respiration (Krebs cycle) KEGG PATHWAY: MAP00020. (B) Components involved in βGP degradation to glycerol and orthophosphate.
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It was reported that 2-oxoglutarate (α-ketoglutarate deriva-
tive) is a precursor of hydroxyproline, which is essential amino
acid for bone protection.49 Interestingly, in our data 2-oxo-
glutarate shows a significant increase during osteogenic treat-
ment compared to untreated control which could support its
importance in bone protection.
Conclusion
In this study, extracellular metabolites were sampled and ana-
lysed at diﬀerent time points during MSC osteogenic induction
in vitro, leading to the identification of diﬀerentially regulated
compounds linked to cellular changes in culture.
The therapeutic potential of mesenchymal stem cells for
applications in regenerative medicine and drug discovery has
warranted a number of investigations targeting conditions
such as osteoporosis and other conditions where skeletal
tissue is compromised. Studies on osteogenic induction
require the development of in-line, non-destructive characteris-
ation methodologies to be able to phenotype MSCs during
diﬀerentiation and limit the requirement for sacrificial cul-
tures needed for most cellular and molecular techniques. In
our study, for the first time, LC-MS-based footprinting with
multi- and univariate analyses has been used for the non-
destructive characterisation of MSC diﬀerentiation. OPLS-DA
analysis from MSCs in undiﬀerentiated and osteogenically-
induced states showed significant and reproducible changes
demonstrated by OPLS-DA scores plots from metabolic foot-
prints of each condition. The MSC culture samples analysed
showed clear metabolomic changes during osteogenesis, with
a particular prominence of compounds linked to cell respira-
tion and the production of orthophosphate, which plays an
important role in ALP level during bone diﬀerentiation.
Further analysis of these metabolomic changes compared to
cell proliferation dynamics will be useful to refine the profile
of diﬀerentiation-related compounds.
Trends of individual OPLS-DA scores plots revealed MSC-
related metabolic signatures, and were also able to clearly dis-
criminate between medium samples from undiﬀerentiated
and OS treated cultures. Changes were followed during the
15-day diﬀerentiation kinetics and showed gradual shifts in
the metabolomic profile of the culture medium. LC-MS spent
culture medium analysis enabled the fine characterisation of
stem cell environment, and showed that it can generate a
chemofootprint of diﬀerentiated cells amenable to real-time
analysis of therapeutic cells in culture. These observations
confirm the power of LC-MS to screen chemical compounds
present in the cellular environment and quantitatively
measure cell-based diﬀerences non-destructively. Combined to
stable isotope assisted approaches,20,50 this LC-MS technology
could be used for future stem cell metabolite profiling to
quantify intracellular metabolites involved in specific stages of
diﬀerentiation and investigate specific pathways identified by
the metabolite footprinting analysis in the current study.
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